Successful salvage treatment of native valve Enterococcus faecalis infective endocarditis with telavancin: two case reports

Abstract

Infective endocarditis (IE) one-year mortality rates approach 40%. Here, we report two native valve Enterococcus faecalis IE cases in patients successfully treated with telavancin. An 88-year-old with mitral valve endocarditis and a penicillin allergy, initially treated with intravenous vancomycin, was switched to telavancin. A 69-year-old, who previously received amoxicillin and intravenous vancomycin for presumed enterococcal bacteraemia, was diagnosed with dual valve endocarditis for which he received telavancin. Both received six weeks of telavancin. Neither had telavancin-related adverse events, evidence of infection at six months, nor required telavancin dosing adjustments. Documented use of novel treatments for serious enterococcal infections is needed.

Keywords:

• Native valve endocarditis
• vegetation
• enterococcal
• telavancin

Disclosure statement

Dr. Hassoun serves on the speaker's bureau for Theravance.